Member area login
You don't have or don't remember the password!
Click Here
Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

--------------------

ISSN print: 0393 – 0564
ISSN digital: 0392- 7091



Articoli con TAG: emoglobina glicata

Emoglobina glicata (HbA1c): confronto tra gli analizzatori Premier Hb9210 e ADAMStm A1c HA-8180V
Glycated hemoglobin (HbA1c): Comparison between Premier Hb9210 and ADAMStm A1c HA-8180V analyzers
<p>Introduction: in this study we evaluated the analytical performance of the Trinity Biotech HbPremier Hb9210 (Bray, Ireland/Kansas city, US), a boronate affinity chromatography-based high performance liquid chromatography (HPLC) system for the measurement of glycated hemoglobin. The ADAMSTM A1c HA-8180V (ARKRAY, Inc., Kyoto, Japan) analyzer was used for the comparison.<br />Methods: three pool of blood (L1, L2, L3) and two control materials (B1, B2) were used to evaluate analytical precision of the HbPremier Hb9210, analyzing five replicates of each sample per day for five days. For the comparison, blood specimens were analyzed according to the Clinical and Laboratory Standard Institute (CLSI) guidelines. Both the available reference systems (IFCC, NGSP) were used.<br />Results: the total CVs of for low, medium and high values of the three pools (L1, L2, L3) were 0.68%, 1.72%, 1.31% respectively; and were 1.57%, 1.38% for low, and medium values (B1, B2) of the two controls when the values were expressed in mmol/mol (SI units) and 0.39%, 1.18%, 1.08% (L1, L2, L3), 0.95%, 1.07% (B1, B2) when the values were reported in % (NGSP units). Passing-Bablok regression used for the comparison of methods showed a small proportional error (slope 1.05, 95%CI: 1.02-1.07) using the IFCC reference system (mmol/mol); the error was not present with the NGSP (%). The bias found was -1.87 mmol/mol (95%CI: -4.33- 0.58) and -0.17% (95%CI: -0.39-0.05).<br />Discussion: the analytical performances of HbPremier Hb9210 have been successfully verified. The instrument performs well and provides results in good agreement with those obtained with the ADAMS analyzer.</p>
Biochimica Clinica ; 46(1) 062-067
Contributi Scientifici - Scientific Papers
 
Riscontro occasionale di una condizione emolitica mediante la determinazione di HbA1c in elettroforesi capillare
Casual finding of a hemolytic condition through the determination of HbA1c by capillary electrophoresis.
<p>HbA1c is a major hemoglobin characterized by nonenzymatic binding of glucose to the N-terminal valine residue of the hemoglobin &beta;-chain, which reflects average glucose levels during the erythrocyte lifespan. This test has been recommended for diabetes monitoring and even for diagnosis, as well as in assessing the risk for chronic complications in diabetic patients. Therefore, an accurate measurement of HbA1c is extremely important. However, the reliability of HbA1c is impaired in certain clinical conditions, such as hemolytic anemia, blood transfusion, renal disease, and pregnancy, that increase the erythrocyte turnover or reduce its lifespan. We report the case of a 38-years-old woman with previous history of high fasting plasma glucose level who underwent routine laboratory assessment. The analysis of HbA1c by capillary electrophoresis (CE) showed an atypical profile with a clear presence of abnormal hemoglobin that did not allow to obtain a reliable result for HbA1c. The same sample analyzed by HPLC showed, the presence of an abnormal Hb and obtained a different result for HbA1c. Subsequently, the analysis of hemoglobin fractions in CE (using Hemoglobin kit- Sebia) confirmed an atypical profile with the presence of an abnormal hemoglobin peak (27.3%) in the &ldquo;zone Z15&rdquo; and low HbA2 (0.5%). The molecular investigation of the globin genes highlighted the presence of three mutations of the &alpha;-genes compatible with HbH disease. The HbH disease is responsible for a hemolytic condition that is associated with reduced erythrocyte survival, making it impossible to use HbA1c for diagnosis and monitoring the glycemic status in this patient. The use of separative technologies, such as CE and HPLC, has been useful to detect a thalassemic defect, which must be reported to allow correct diagnostic conclusions. In this condition, the introduction of alternative biomarkers like glycated albumin (GA) is thought to be more reliable than HbA1c, since GA values are not influenced by the modifications of the erythrocyte lifespan.</p>
Biochimica Clinica ; 46(3) e11-e14
Casi Clinici - Case Report